|
|
|
|
| LEADER |
02779nam a2200469 4500 |
| 001 |
978-3-319-63757-0 |
| 003 |
DE-He213 |
| 005 |
20191024031650.0 |
| 007 |
cr nn 008mamaa |
| 008 |
171103s2018 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319637570
|9 978-3-319-63757-0
|
| 024 |
7 |
|
|a 10.1007/978-3-319-63757-0
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Early Phase Cancer Immunotherapy
|h [electronic resource] /
|c edited by Sandip Pravin Patel, Razelle Kurzrock.
|
| 250 |
|
|
|a 1st ed. 2018.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2018.
|
| 300 |
|
|
|a XI, 331 p. 24 illus., 15 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Current Cancer Research,
|x 2199-2584
|
| 505 |
0 |
|
|a Chapter 1 Primer on Cancer Immunotherapy and the Targeting of Native Proteins -- Chapter 2 Pharmacokinetics and Pharmacodynamics of Immunotherapy -- Chapter 3 Immunotherapeutic Biomarkers and Selection Strategies -- Chapter 4 Radiographic Evaluation of Immunotherapy -- Chapter 5 Cellular Therapy -- Chapter 6 Combinatorial Checkpoint Blockade Immunotherapy and Radiation -- Chapter 7 Early Phase Cancer Immunotherapy -- Chapter 8 Immune Checkpoint Combinations with Inflammatory Pathway Modulators -- Chapter 9 Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials -- Chapter 10 Thoracic Immunotherapy.
|
| 520 |
|
|
|a This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 http://scigraph.springernature.com/things/product-market-codes/B11001
|
| 700 |
1 |
|
|a Patel, Sandip Pravin.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Kurzrock, Razelle.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319637563
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319637587
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319876283
|
| 830 |
|
0 |
|a Current Cancer Research,
|x 2199-2584
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-63757-0
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
